Litcius/Paper detail

NIR-II-triggered doxorubicin release for orthotopic bladder cancer chemo-photothermal therapy

Zhiduo Sun, Weiyun Zhang, Zhichao Ye, Yuan Li, Manli Fu, Xiaoming Liu, Huageng Liang, Heyou Han

2022Nanoscale17 citationsDOI

Abstract

realized NIR-II-triggered gas-driven drug burst release, and the doxorubicin release was 2.79 times higher within 1 h after NIR-II irradiation. Also, the HTCC-modified nanocarriers significantly enhanced the bladder mucosal permeability as well as long-term drug retention, and the penetration efficiency of DNAH increased by 144%. In the orthotopic bladder cancer model, the tumor suppression rate and mouse survival time were significantly improved. DNAH showed potent inhibition of the orthotopic bladder tumor growth owing to the enhanced penetration and drug delivery. This work presents a potential drug delivery nanocarrier, which is promising for optimized bladder mucosal permeability and controlled drug burst release.

Topics & Concepts

Photothermal therapyNanocarriersDoxorubicinDrug deliveryBladder cancerPhotothermal effectDrugPharmacologyChemistryMaterials scienceMedicineNanotechnologyCancerChemotherapySurgeryInternal medicineNanoplatforms for cancer theranosticsBladder and Urothelial Cancer TreatmentsNanoparticle-Based Drug Delivery
NIR-II-triggered doxorubicin release for orthotopic bladder cancer chemo-photothermal therapy | Litcius